Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
暂无分享,去创建一个
S. O’Day | He-jing Wang | L. Piro | R. Deck | P. Boasberg | G. Gammon | Maureen Martin | T. Kristedja | Hannah Kim | P. Ames | P. Fournier | K. Shinn | S. O'Day